Brightgene Bio-medical Technology Co (SHSE:688166) ROC %: 0.00% (As of Mar. 2026)


SHSE:688166 Brightgene Bio-medical Technology Co Ltd SHSE:688166
84 GF Score
Price ¥31.19
GF Value ¥38.49
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Brightgene Bio-medical Technology Co ROC %?

Brightgene Bio-medical Technology Co SHSE:688166 +4.66% 84 ROC % is 0.00% as of Mar. 2026. GuruFocus rates SHSE:688166 with a GF Score™ of 84/100 and a GF Value™ of ¥38.49 (Modestly Undervalued). The stock has 7 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Brightgene Bio-medical Technology Co's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was 0.00%.

As of today (2026-07-11), Brightgene Bio-medical Technology Co's WACC % is 13.20%. Brightgene Bio-medical Technology Co's ROC % is 2.77% (calculated using TTM income statement data). Brightgene Bio-medical Technology Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Brightgene Bio-medical Technology Co  (SHSE:688166) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Brightgene Bio-medical Technology Co's WACC % is 13.20%. Brightgene Bio-medical Technology Co's ROC % is 2.77% (calculated using TTM income statement data). Brightgene Bio-medical Technology Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Brightgene Bio-medical Technology Co ROC % Related Terms


Brightgene Bio-medical Technology Co ROC % Historical Data

* Premium members only.

The historical data trend for Brightgene Bio-medical Technology Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brightgene Bio-medical Technology Co ROC % Chart

Brightgene Bio-medical Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.24 8.27 6.63 5.62 2.38

Brightgene Bio-medical Technology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 1.40 4.08 0.00 0.00
SHSE:688166
84GF Score
Brightgene Bio-medical Technology Co Ltd SHSE:688166
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brightgene Bio-medical Technology Co ROC % Calculation

Brightgene Bio-medical Technology Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=110.198 * ( 1 - 0% )/( (4212.149 + 5043.665)/ 2 )
=110.198/4627.907
=2.38 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5153 - 352.958 - ( 765.353 - max(0, 1052.385 - 1640.278+765.353))
=4212.149

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5824.842 - 272.981 - ( 961.064 - max(0, 1280.306 - 1788.502+961.064))
=5043.665

Brightgene Bio-medical Technology Co's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=93.92 * ( 1 - 100% )/( (5043.665 + 5007.074)/ 2 )
=0/5025.3695
=0.00 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5824.842 - 272.981 - ( 961.064 - max(0, 1280.306 - 1788.502+961.064))
=5043.665

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6535.052 - 212.604 - ( 1395.351 - max(0, 991.268 - 2306.642+1395.351))
=5007.074

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 0.00% mean?
Brightgene Bio-medical Technology Co (SHSE:688166) has a ROC % of 0.00% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Brightgene Bio-medical Technology Co and its competitors.
Is Brightgene Bio-medical Technology Co's ROC % too high?
Brightgene Bio-medical Technology Co's current ROC % is 0.00%. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's ROC % compare to VRTX and REGN?
Brightgene Bio-medical Technology Co's ROC % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Brightgene Bio-medical Technology Co and its competitors. Brightgene Bio-medical Technology Co's current ROC % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.49, compared to a current price of ¥31.19 — trading 19% below its estimated fair value. The current ROC % is 0.00%. Brightgene Bio-medical Technology Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current ROC % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?

Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued. The current stock price of ¥31.19 is trading 19% below its estimated GF Value™ of ¥38.49. GuruFocus considers Brightgene Bio-medical Technology Co to be Modestly Undervalued.

Key valuation signals for SHSE:688166:

  • ROC %: 0.00%
  • GF Value™: ¥38.49 vs. price of ¥31.19 (19% below fair value)
  • GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Brightgene Bio-medical Technology Co Business Description

Address No. 218 Xinghu Street, Buildings C25-C28, Nanotechnology Park, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
84GF Score

Get the complete analysis for SHSE:688166

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥31.19
Price
¥38.49
GF Value